Eric Schoen - Cassava Sciences Chief Officer
| SAVA Stock | USD 3.98 0.15 3.92% |
Executive
Mr. Eric J. Schoen was appointed Chief Financial Officer of the Company effective on or before November 7, 2018. Mr. Schoen served in numerous financial leadership roles. Mr. Schoen joins the Company from his present role as Interim Chief Financial Officer of Austin Pain Acquisition, LLC, a holding company which owns an ambulatory surgery center and manages numerous pain management practices. From 2011 to 2017, he served as Vice President, Senior Vice President, Finance and Chief Accounting Officer of Vermillion, Inc., a bioanalyticalbased womens health company focused on gynecologic disease. From 2010 to 2011, he served as Corporationrationrate Controller for Vermillion, Inc. Mr. Schoen served as Revenue Controller for Borland Software from 2007 to 2010. Mr. Schoen also began his career and spent nine years with PricewaterhouseCoopers, most recently as a Manager in the audit and assurance, transaction services and global capital markets practices since 2018.
| Age | 56 |
| Tenure | 6 years |
| Address | 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731 |
| Phone | 512 501 2444 |
| Web | https://www.cassavasciences.com |
Eric Schoen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Eric Schoen against Cassava Sciences stock is an integral part of due diligence when investing in Cassava Sciences. Eric Schoen insider activity provides valuable insight into whether Cassava Sciences is net buyers or sellers over its current business cycle. Note, Cassava Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cassava Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Eric Schoen over six months ago Disposition of 1000 shares by Eric Schoen of Cassava Sciences at 33.0 subject to Rule 16b-3 | ||
Eric Schoen over a year ago Acquisition by Eric Schoen of 150000 shares of Cassava Sciences subject to Rule 16b-3 |
Cassava Sciences Management Efficiency
The company has return on total asset (ROA) of (0.456) % which means that it has lost $0.456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1098) %, meaning that it created substantial loss on money invested by shareholders. Cassava Sciences' management efficiency ratios could be used to measure how well Cassava Sciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.61. The current year's Return On Capital Employed is expected to grow to -0.73. At present, Cassava Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 7.9 M, whereas Total Assets are forecasted to decline to about 114.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Thomas | Krystal Biotech | N/A | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Penelope Markham | Biovie Inc | 58 | |
| Melissa Gaines | Annovis Bio | N/A | |
| Patrick Baumhof | CureVac NV | N/A | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| Bobby Horn | Cognition Therapeutics | N/A | |
| Terrie Kellmeyer | Anavex Life Sciences | N/A | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| Phillip MD | Vir Biotechnology | 48 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Hubert MD | Krystal Biotech | 55 | |
| Lori MBA | Axsome Therapeutics | 46 | |
| Tony Redmond | Exelixis | N/A | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Friso Postma | BioXcel Therapeutics | N/A | |
| Anne MD | Exelixis | N/A | |
| Ari Maizel | Axsome Therapeutics | N/A | |
| Arran Attridge | Vir Biotechnology | N/A | |
| Jeff MD | Vir Biotechnology | 63 | |
Management Performance
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.46 |
Cassava Sciences Leadership Team
Elected by the shareholders, the Cassava Sciences' board of directors comprises two types of representatives: Cassava Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cassava. The board's role is to monitor Cassava Sciences' management team and ensure that shareholders' interests are well served. Cassava Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cassava Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James MD, Chief Officer | ||
| Christopher JD, Company VP | ||
| Remi Barbier, Chairman of the Board and Presidentident, CEO | ||
| Michael Zamloot, Senior Operations | ||
| Jaren Landen, Chief Officer | ||
| Michael PharmD, Senior Affairs | ||
| Lindsay Burns, Senior Neuroscience | ||
| Christopher Cook, Sr Counsel | ||
| Eric Schoen, Chief Officer | ||
| Nadav MD, Chief Director | ||
| Freda Nassif, Chief Officer | ||
| Richard Barry, Executive Board | ||
| George Thornton, Senior Technology |
Cassava Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cassava Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 85.5 M | ||||
| Shares Outstanding | 48.11 M | ||||
| Shares Owned By Insiders | 13.37 % | ||||
| Shares Owned By Institutions | 29.95 % | ||||
| Number Of Shares Shorted | 18.57 M | ||||
| Price To Book | 1.24 X | ||||
| Gross Profit | (68.03 M) | ||||
| EBITDA | (95.69 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cassava Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cassava Sciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cassava Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cassava Sciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Cassava Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Cassava Stock refer to our How to Trade Cassava Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cassava Sciences. If investors know Cassava will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cassava Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.38) | Return On Assets (0.46) | Return On Equity (0.11) |
The market value of Cassava Sciences is measured differently than its book value, which is the value of Cassava that is recorded on the company's balance sheet. Investors also form their own opinion of Cassava Sciences' value that differs from its market value or its book value, called intrinsic value, which is Cassava Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cassava Sciences' market value can be influenced by many factors that don't directly affect Cassava Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cassava Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cassava Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cassava Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.